GM-CSF neutralization with lenzilumab in severe COVID-19 pneumonia: a case-cohort study
…, R Palraj, AS Dababneh, G Chappell, D Chappell… - Mayo Clinic …, 2020 - Elsevier
… Dababneh MD a , Gabrielle Chappell l , Dale Chappell MD, MBA l , Omar Ahmed PharmD
l , Reona Sakemura MD, PhD d e , Cameron Durrant MD, MBA l , Saad S. Kenderian MD d e f …
l , Reona Sakemura MD, PhD d e , Cameron Durrant MD, MBA l , Saad S. Kenderian MD d e f …
Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): a phase 3, randomised, placebo-controlled trial
…, D Chappell, O Ahmed, G Chappell… - The Lancet …, 2022 - thelancet.com
Background The pathophysiology of COVID-19 includes immune-mediated
hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte-macrophage …
hyperinflammation, which could potentially lead to respiratory failure and death. Granulocyte-macrophage …
[HTML][HTML] Lenzilumab efficacy and safety in newly hospitalized Covid-19 subjects: results from the live-air phase 3 randomized double-blind placebo-controlled trial
…, C Durrant, D Chappell, O Ahmed, G Chappell… - medRxiv, 2021 - ncbi.nlm.nih.gov
BACKGROUND: Severe COVID-19 pneumonia results from a hyperinflammatory immune
response (cytokine storm, CS), characterized by GM-CSF mediated activation and trafficking of …
response (cytokine storm, CS), characterized by GM-CSF mediated activation and trafficking of …
[HTML][HTML] An effective mouse model for adoptive cancer immunotherapy targeting neoantigens
K Hanada, Z Yu, GR Chappell, AS Park, NP Restifo - JCI insight, 2019 - ncbi.nlm.nih.gov
The adoptive cell transfer (ACT) of T cells targeting mutated neoantigens can cause
objective responses in varieties of metastatic cancers, but the development of new T cell–based …
objective responses in varieties of metastatic cancers, but the development of new T cell–based …
First clinical use of lenzilumab to neutralize GM-CSF in patients with severe and critical COVID-19 pneumonia
…, AS Dababneh, G Chappell, D Chappell… - Medrxiv, 2020 - medrxiv.org
Background In COVID-19, high levels of granulocyte macrophage-colony stimulating factor (GM-CSF)
and inflammatory myeloid cells correlate with disease severity, cytokine storm, and …
and inflammatory myeloid cells correlate with disease severity, cytokine storm, and …
[PDF][PDF] Emulsion and liposome-based adjuvanted R21 vaccine formulations mediate protection against malaria through distinct immune mechanisms
S Reinke, E Pantazi, GR Chappell… - Cell Reports …, 2023 - cell.com
Adjuvanted protein vaccines offer high efficacy, yet most potent adjuvants remain proprietary.
Several adjuvant compounds are being developed by the Vaccine Formulation Institute in …
Several adjuvant compounds are being developed by the Vaccine Formulation Institute in …
C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR'trial
…, D Chappell, C Durrant, O Ahmed, G Chappell… - Thorax, 2023 - thorax.bmj.com
Objective COVID-19 severity is correlated with granulocyte macrophage colony-stimulating
factor (GM-CSF) and C reactive protein (CRP) levels. In the phase three LIVE-AIR trial, …
factor (GM-CSF) and C reactive protein (CRP) levels. In the phase three LIVE-AIR trial, …
Early lenzilumab treatment of COVID-19 patients using c-reactive protein as a biomarker improves efficacy: results from the phase 3 'LIVE-AIR'trial
…, D Chappell, C Durrant, O Ahmed, G Chappell… - MedRxiv, 2022 - medrxiv.org
Objective The LIVE-AIR trial demonstrated that the anti-GM-CSF monoclonal antibody,
lenzilumab improved the likelihood of survival without invasive mechanical ventilation (SWOV) in …
lenzilumab improved the likelihood of survival without invasive mechanical ventilation (SWOV) in …
C-reactive protein as a biomarker for improved efficacy of lenzilumab in patients with COVID-19: results from the LIVE-AIR trial
…, W Aronstein, C Durrant, D Chappell, G Chappell… - Chest, 2021 - journal.chestnet.org
PURPOSE: The hyperinflammatory cytokine storm (CS) of COVID-19 is mediated by GM-CSF
leading to release of downstream inflammatory chemokines, cytokines, and corresponding …
leading to release of downstream inflammatory chemokines, cytokines, and corresponding …
COVID-19 associated chronic ARDS successfully treated with lenzilumab
…, R Rasool, G Chappell, C Durrant, D Chappell - 2020 - osf.io
Background: Myeloid hyperinflammation leading to T-cell immune suppression and
lymphocytopenia is a hallmark of severe COVID-19. Granulocyte macrophage-colony stimulating …
lymphocytopenia is a hallmark of severe COVID-19. Granulocyte macrophage-colony stimulating …